CDTTW — Conduit Pharmaceuticals Inc.
NASDAQ
$0.01
+$0.00 (+17.17%)
Conduit Pharmaceuticals Inc. (CDTTW) common stock listed on NASDAQ. It is led by Andrew Regan, based in 4581 Tamiami Trail North, Naples, FL, United States, 34103, with about 4 employees. CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.
Net income was -$7.1M.
Use this CDTTW page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the CDTTW quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the CDTTW SEC filings page. Lician reads the product cache first so this HTML stays unique to Conduit Pharmaceuticals Inc. even when a live quote feed is slow.
About Conduit Pharmaceuticals Inc.
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.
CDTTW Key Statistics
Market Cap
$0.00M
Volume
10,261
Previous Close
$0.01
Day Range
$0.01 – $0.01
EPS
-$20.53
Revenue
$0.00
Net Income
-$17.80M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
4
CDTTW Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 |
| Net Income | -$17.80M | -$535.00K | -$4.89M |
| EPS (Diluted) | -$20.53 | -$8.92 | -$0.13 |
Total Assets
$4.19M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$600.00K
Operating Cash Flow
-$9.68M
Free Cash Flow
$0.00
Conduit Pharmaceuticals Inc. Company Information
- Founder, CEO & Director
- Andrew Regan
- Headquarters
- 4581 Tamiami Trail North, Naples, FL, United States, 34103
- Website
- www.cdtequity.com
- Phone
- 646 491 9132
- IPO / Founded
- 2023-09-25